TLR-9-activated B cells played a central role in generating CD8 T cells with potent anti-tumor capacity in vitro, because depletion of B cells from the CpG-treated pmel-1 cultures led to deficient CD8 T cell responses in B57L/6 mice suffering from melanoma after injection. This evidence concerns the gene TLR9 and neoplasm.